Asparaginase side effects in leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at the side effects of the drug asparaginase in children and young adults with certain types of leukemia or lymphoma. It aims to better understand and manage these side effects to improve treatment safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia.
- You are enrolled on a study called INITIALL and are within 10 days of starting your next treatment.
- Your next treatment must be either standard therapy or a specific study called SJALL23T. If you are on SJALL23T, you cannot be getting a drug called venetoclax.
- You or your legal guardian must be willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study examines how your immune system (specifically T cells) reacts to asparaginase, a drug used to treat acute lymphoblastic leukemia. By understanding these reactions, doctors hope to predict and prevent allergic or sensitivity problems during your cancer treatment.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This study tests CM4620 to reduce how severe pancreatitis becomes in children and young people with leukemia/lymphoma who develop pancreatitis after receiving a drug called asparaginase. It aims to improve outcomes by calming the inflammation of the pancreas.
Hear when a new Drug Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.